[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Mackay Medical College\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":132},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,69,90,111],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100596098","sunam-protocol-for-managing-bpsd-100596098",false,"NCT07041034","SUNAM Protocol for Managing BPSD","The Effectiveness of the Systematic Unmet Needs Assessment and Management (SUNAM) Protocol on Behavioral and Psychological Symptoms of Institutionalized Residents With Dementia","Inclusion Criteria:\n\n* Diagnosed with dementia or documented as having dementia in medical records.\n* Currently residing in the long-term care facility.\n\nExclusion Criteria:\n\n* Diagnosed with schizophrenia.\n* The resident's legal representative does not provide consent for participation.","ALL","65 Years","110 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study evaluates the effectiveness of the Systematic Unmet Needs Assessment and Management (SUNAM) Protocol, an algorithm-based intervention developed from the unmet needs theory of BPSD, in reducing Behavioral and Psychological Symptoms of Dementia (BPSD) among institutionalized residents. Both the experimental and control groups received 100 minutes of BPSD foundational education and 100 minutes of VR simulation training. The experimental group received an additional 150 minutes of SUNAM protocol training. The study aims to determine whether integrating SUNAM into caregiver training enhances BPSD assessment, management, and reduction by addressing unmet needs.",[27],"Dementia",[29,30],"SUNAM Protocol","Behavioral and Psychological Symptoms","RECRUITING","2026-06-04",{"date":34,"type":35},"2026-06-08","ACTUAL",{"date":37,"type":35},"2025-12-20",{"date":39,"type":21},"2027-03-31",{"name":41,"class":42},"Mackay Medical College","OTHER",2,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100458874","efficacysafety-of-midurethral-sling-100458874","NCT05255289","Efficacy\u002FSafety of Midurethral Sling","Evaluation of Efficacy and Safety of Midurethral Slings in Women With Stress Incontinence","Inclusion Criteria:\n\n* Clinical diagnosis of stress urinary incontience\n* Have urodynamic investigations before and after operation.\n\nExclusion Criteria:\n\n* Exclusion criteria will be a history of (1) cardiovascular, (2) neurological, or (3) other medical (such as diabetes or inflammation) problems as well as (4) patients who received a concomitant surgical procedure.","FEMALE","30 Years","100 Years",{"count":55,"type":21},200,[24],"The trans-obturator tape (TOT), which exhibits a satisfactory cure rate and a relatively diminished invasiveness, has been increasingly accepted as a surgical treatment of stress urinary incontinence (SUI) patients. Nevertheless, in contrast to the well-recognized therapeutic benefit of the enhanced resistance to the bladder continence during urine storage, if the voiding function of the bladder adapts to the TOT-enhanced outlet resistance has not been adequately investigated. This study retrospectively assayed the voiding efficacy of each voiding cycle, to clarify if the thermodynamic efficacy of the bladder was modified in response to the TOT surgery.",[59],"Stress Urinary Incontinence","2025-08-30",{"date":62,"type":35},"2025-09-05",{"date":64,"type":35},"2021-03-08",{"date":66,"type":21},"2026-03",{"name":41,"class":42},1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":68},"100594914","comparing-treatments-for-overactive-bladder-in-taiwan-a-study-of-outcomes-100594914","NCT07025642","Comparing Treatments for Overactive Bladder in Taiwan: A Study of Outcomes","Outcome of Different Treatments of Overactive Bladder in Taiwan","Inclusion Criteria:\n\n\\- female overactive bladder\n\nExclusion Criteria:\n\n* DM, CVA, other medical problems",{"count":77,"type":21},60,[24],"Overactive bladder (OAB) syndrome is a prevalent condition that significantly impairs patients' quality of life. Standard therapeutic strategies include oral antimuscarinics (e.g., solifenacin), beta-3 adrenergic agonists (e.g., mirabegron), and intradetrusor injection of botulinum neurotoxin type A (BoNTA). Despite their clinical utility, these treatments share a common mechanism of action: suppression of detrusor muscle contractility. However, it remains unclear whether such suppression translates to a reduction in the overall mechanical work output of the bladder during micturition.\n\nTo address this question, our research proposes to assess how mirabegron, solifenacin, and BoNTA influence bladder function from a thermodynamic perspective. We will apply pressure-volume analysis (PVA), a methodology traditionally used in cardiac physiology, to quantify the mechanical work performed by the bladder per voiding cycle. This approach enables a direct measurement of the energy expenditure required for bladder emptying, offering insights beyond standard urodynamic parameters.\n\nFurthermore, emerging data suggest BoNTA may exert additional effects beyond parasympathetic inhibition. Specifically, recent studies have demonstrated that BoNTA also inhibits norepinephrine release from sympathetic hypogastric nerve terminals. Since modulation of sympathetic activity-particularly via the hypogastric nerve-has been implicated in regulating bladder compliance and storage function, we hypothesize that BoNTA may influence bladder compliance through this secondary mechanism. To explore this, we will employ volume-pressure analysis (also abbreviated as PVA), which graphically represents the dynamic relationship between bladder volume and pressure throughout voiding cycles, thus capturing real-time changes in compliance.\n\nComparative studies of mirabegron, solifenacin, and BoNTA will allow us to differentiate their respective impacts on bladder work and compliance. Mirabegron, which selectively activates beta-3 adrenergic receptors, has minimal influence on overall sympathetic tone. In contrast, solifenacin not only antagonizes muscarinic receptors but may also indirectly potentiate sympathetic tone by reducing parasympathetic influence. BoNTA, with its dual action on both autonomic pathways, provides a unique model to dissect these neural mechanisms.\n\nTo extend our findings from clinical observations to preclinical validation, we aim to develop and utilize a spinal cord injury (SCI) rat model that recapitulates the bladder dysfunction observed in neurogenic detrusor overactivity (NDO)-a condition for which mirabegron, solifenacin, and BoNTA are also commonly prescribed. By applying both thermodynamic and compliance-focused PVA techniques in this animal model, we seek to construct a foundational database characterizing how these drugs modulate bladder function in a controlled, reproducible setting.\n\nIn summary, this project integrates a novel application of pressure- and volume-based analyses to quantify the mechanical and compliance-related effects of established OAB therapies in both human patients and a translational animal model. The findings will provide new mechanistic insights into how these treatments alter bladder physiology, potentially guiding future therapeutic strategies and optimizing drug selection for individualized patient care.",[81],"Overactive Bladder (OAB)","2025-06-13",{"date":84,"type":35},"2025-06-17",{"date":86,"type":21},"2025-07-01",{"date":88,"type":21},"2026-12-01",{"name":41,"class":42},{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":51,"minAge":97,"maxAge":53,"enrollmentInfo":98,"targetDuration":4,"studyType":99,"phases":4,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":68},"100514341","efficacy-of-conservative-treatments-for-urinary-incontinence-in-women-100514341","NCT05977231","Efficacy of Conservative Treatments for Urinary Incontinence in Women","Evaluation of Efficacy of Conservative Treatments in Women With Urinary Incontinence","Inclusion Criteria:\n\n* Adult female patient diagnosed with urinary incontinence through clinical assessment\n* Diagnosed at Mackay Memorial Hospital and underwent non-surgical treatment and subsequent follow-up.\n\nExclusion Criteria:\n\n* Choosing invasive or surgical treatment options (such as bladder botulinum toxin injection, urethral sling surgery).\n* Unable to comply with regular follow-up for at least one year.\n* Pregnant women\n* Patients with a history of neuromuscular disorders.","20 Years",{"count":77,"type":21},"OBSERVATIONAL","To conduct a retrospective study to examine the effect of these conservative treatments to the symptoms and quality of life of patients with urinary incontinence. The investigators will use both subjective and objective assessment parameters, such as self-report symptoms, bladder diary, pad test and urodynamic study to access the improvement.",[102],"Urinary Incontinence","2023-07-28",{"date":105,"type":35},"2023-08-04",{"date":107,"type":35},"2023-01-01",{"date":109,"type":21},"2028-12-31",{"name":41,"class":42},{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":118,"targetDuration":4,"studyType":99,"phases":4,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":68},"100491735","efficacysafety-of-urogynecology-synthetic-mesh-surgery-100491735","NCT05682989","Efficacy\u002FSafety of Urogynecology Synthetic Mesh Surgery","Evaluation of Efficacy and Safety of Urogynecology Synthetic Mesh Surgery in Women With Pelvic Organ Prolapse","Inclusion Criteria:\n\n* Pelvic organ prolapse patients with objective \u002F subjective voiding dysfunctions\n* Underwent surgery for symptomatic POP ≥ stage II (POP-Q system)\n\nExclusion Criteria:\n\n* Patients with a history of pelvic radiation.\n* Patients with a history of vesico-\u002Frecto-\u002Furethra-vaginal fistula\n* Patients unable to be followed up.",{"count":119,"type":21},150,"This is a retrospective cohort study, aiming at analyzing the efficacy and safety of mesh surgery in pelvic organ prolapse. The synthetic mesh for pelvic organ prolapse include transvaginal mesh or laparotomy, laparoscope, or robotic-assisted laparoscopic sacrocolpopexy with mesh augmentation. The investigators would like to evaluate the efficacy and safety, such as recurrence rates and complication rates for women who underwent urogynecology mesh surgery.",[122,123],"Pelvic Organ Prolapse","Stage III and IV High Grade Pelvic Organ Prolapse","2023-04-02",{"date":126,"type":35},"2023-04-05",{"date":128,"type":35},"2022-08-01",{"date":130,"type":21},"2027-12-31",{"name":41,"class":42},""]